Thromb Haemost 1998; 80(04): 677-685
DOI: 10.1055/s-0037-1615441
Rapid Communication
Schattauer GmbH

Porcine Platelet von Willebrand Antigen II (vW AgII): Inhibitory Effect on Collagen-induced Aggregation and Comparative Distribution with Human Platelets

Teresa Royo
1   From the Cardiovascular Research Center, CSIC-Hospital de la Santa Creu i Sant Pau-UAB
2   From the Institut de Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
,
Matilde Vidal
1   From the Cardiovascular Research Center, CSIC-Hospital de la Santa Creu i Sant Pau-UAB
,
Lina Badimon
1   From the Cardiovascular Research Center, CSIC-Hospital de la Santa Creu i Sant Pau-UAB
› Author Affiliations
Supported in part by FISss 95/1381, Marató TV3-Malaltíes Cardíaques/ 96-10, Fundación de Investigación Cardiovascular (FIC)-Catalana Occidente and Fundación Española de Arteriosclerosis (FEA)
Further Information

Publication History

Received 04 December 1997

Accepted after resubmission 15 May 1998

Publication Date:
08 December 2017 (online)

Summary

Von Willebrand factor (vWF) is synthesized by human endothelial cells and megakaryocytes as a large precursor, the pre-provWF, which is finally cleaved into the propolypeptide of vWF (pp-vWF) and the mature vWF. We have purified in parallel the pp-vWF and the GP IIb-IIIa from porcine platelets. The N-terminus comparative analysis of porcine pp-vWF with respect to other species revealed more than a 75% and 65% homology with the bovine and human pp-vWF, respectively. Purified pp-vWF inhibited collagen-induced platelet aggregation in porcine platelet rich plasma (PRP) and specifically binds to collagen. Polyclonal antibody pabBp19 against the purified protein was prepared and characterized by ELISA, Western-blot and immunocytochemistry. The distribution of pp-vWF in soluble and membrane fractions from pig platelets has been performed by immunolabeling detection. pabBp19 did not blot human platelet lysates but human pp-vWF was detectable using the antibody Frieda 013091. Cell distribution and quantification studies of human and porcine platelet pp-vWF showed that the protein exists in the soluble and membrane fractions and its pattern is similar in both species.

 
  • References

  • 1 Baumgartner HR, Tscopp TB, Meyer D. Shear rate dependent inhibition of platelet adhesion and aggregation on collagenous surfaces by antibodies to human Factor VIII/von Willebrand factor. Br J Haematol 1980; 44: 127-39.
  • 2 Turitto VT, Weiss HJ, Baumgartner HR. Decreased platelet adhesion on vessel segments in von Willebrand‘s disease: A defect in initial platelet attachment. J Lab Clin Med 1983; 102: 551-64.
  • 3 Turitto VT, Weiss HJ, Zimmerman TS, Sussman II. Factor VIII/von Wille-brand factor in subendothelium mediates platelet adhesion. Blood 1985; 65: 823-31.
  • 4 Hoyer LW. The Factor VIII complex: Structure and function. Blood 1981; 58: 1-13.
  • 5 Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 1987; 262: 8443-6.
  • 6 Takahashi Y, Kalafatis M, Girma JP, Sewerin K, Andersson LO, Meyer D. Localization of a factor VIII binding domain on a 34 kilodalton fragment of the N-terminal portion of von Willebrand factor. Blood 1987; 70: 1679-82.
  • 7 Houdijk WP, Sakariassen KS, Nievelstein PF, Sixma JJ. Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III. J Clin Invest 1985; 75: 531-40.
  • 8 Fressinaud E, Baruch D, Rothschild C, Baumgartner HR, Meyer D. Platelet von Willebrand factor: Evidence for its involvement in platelet adhesion to collagen. Blood 1987; 70: 1214-7.
  • 9 Jaffe EA, Hoyer LW, Nachman RL. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest 1973; 52: 2757-64.
  • 10 Jaffe EA, Hoyer LW, Nachman RL. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci USA 1974; 71: 1906-9.
  • 11 Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: Processing steps and their intracellular localization. J Cell Biol 1984; 99: 2123-30.
  • 12 McCarroll DR, Levin EG, Montgomery RR. Endothelial cell synthesis of von Willebrand antigen II, von Willebrand factor, and von Willebrand factor/von Willebrand antigen II complex. J Clin Invest 1985; 75: 1089-95.
  • 13 Wagner DD, Olmsted JB, Marder VJ. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol 1982; 95: 355-60.
  • 14 Wagner DD, Saffaripour S, Bonfanti R, Sadler JE, Cramer EM, Chapman B, Mayadas TN. Induction of specific storage organelles by von Willebrand factor propolypeptide. Cell 1991; 64: 403-13.
  • 15 Sporn LA, Chavin SI, Marder VJ, Wagner DD. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest 1985; 76: 1102-6.
  • 16 Cramer EM, Meyer D, leMenn R, Breton-Gorius J. Eccentric localization of von Willebrand factor in an internal structure of platelet α-granule resembling that of Weibel-Palade bodies. Blood 1985; 66: 710-3.
  • 17 Bonthron DT, Handin RI, Kaufman RJ, Wasley LC, Orr EC, Mitsock LM, Ewenstein B, Loscalzo J, Ginsburg D, Orkin SH. Structure of pre-pro-von Willebrand factor and its expression in heterologous cells. Nature 1986; 324: 270-3.
  • 18 Bonthron D, Orr EC, Mitsock LM, Ginsburg D, Handin RI, Orkin SH. Nucleotide sequence of pre-pro-von Willebrand factor cDNA. Nucleic Acids Research 1986; 14: 7125-7.
  • 19 Fay PJ, Kawai Y, Wagner DD, Ginsburg D, Bonthron D, Ohlsson-Wilhelm BM, Chavin SI, Abraham GN, Handin RI, Orkin SH, Montgomery RR, Marder VJ. Propolypeptide of von Willebrand factor circulates in blood and is identical to von Willebrand antigen II. Science 1986; 232: 995-8.
  • 20 Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6: 217-46.
  • 21 McCarrol DR, Ruggeri ZM, Montgomery RR. Correlation between circulating levels of von Willebrand‘s antigen II and von Willebrand factor: Discrimination between type I and type II von Willebrand‘s disease. J Lab Clin Med 1984; 103: 704-11.
  • 22 Montgomery RR, Zimmerman TS. Von Willebrand‘s disease antigen II: A new plasma and platelet antigen deficient in severe von Willebrand’s disease. J Clin Invest 1978; 61: 1498-507.
  • 23 Scott JP, Montgomery RR. Platelet von Willebrand’s antigen II: Active release by aggregating agents and a marker of platelet release reaction in vivo. Blood 1981; 58: 1075-80.
  • 24 Hashimoto K, Sekiya F, Takagi J, Tsukada T, Sato F, Saito Y. Activation of phospholipases in platelets by polyclonal antibodies against a surface membrane protein. Biochim Biophys Acta 1992; 1165: 27-31.
  • 25 Hashimoto K, Usui T, Sasaki K, Fujisawa T, Sekiya F, Takagi J, Tsukada T, Saito Y. Immunological detection of propolypeptide of von Willebrand factor on platelet surface. Biochem Biophys Res Commun 1991; 176: 1571-6.
  • 26 Verweij CL, Diergaarde PJ, Hart M, Pannekoek H. Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J 1986; 5: 1839-47.
  • 27 Fujimura Y, Titani K, Holland LZ, Russell SR, Roberts JR, Elder JH, Ruggeri ZM, Zimmerman TS. Von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem 1986; 261: 381-5.
  • 28 Mohri H, Fujimura Y, Shima M, Yoshioka A, Houghten RA, Ruggeri ZM, Zimmerman TS. Structure of the von Willebrand factor domain interacting with glycoprotein Ib. J Biol Chem 1988; 263: 17901-4.
  • 29 Fujimura Y, Titani K, Holland LZ, Roberts JR, Kostel P, Ruggeri ZM, Zimmerman TS. A heparin-binding domain of human von Willebrand factor. Characterization and localization to a tryptic fragment extending from amino acid residue Val-449 to Lys-728. J Biol Chem 1987; 262: 1734-9.
  • 30 Pareti FI, Fujimura Y, Dent JA, Holland LZ, Zimmerman TS, Ruggeri ZM. Isolation and characterization of a collagen binding domain in human von Willebrand factor. J Biol Chem 1986; 261: 15310-5.
  • 31 Pareti FI, Niiya K, McPherson JM, Ruggeri ZM. Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III. J Biol Chem 1987; 262: 13835-41.
  • 32 Takagi J, Fujisawa T, Sekiya F, Saito Y. Collagen-binding domain within bovine propolypeptide of von Willebrand factor. J Biol Chem 1991; 266: 5575-9.
  • 33 Mohri H, Yoshioka A, Zimmerman TS, Ruggeri ZM. Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites. J Biol Chem 1989; 264: 17361-7.
  • 34 Takagi J, Sekiya F, Kasahara K, Inada Y, Saito Y. Inhibition of platelet-collagen interaction by propolypeptide of von Willebrand factor. J Biol Chem 1989; 264: 6017-20.
  • 35 Takagi J, Kasahara K, Sekiya F, Inada Y, Saito Y. A collagen-binding glycoprotein from bovine platelets is identical to propolypeptide of von Willebrand factor. J Biol Chem 1989; 264: 10425-30.
  • 36 Usui T, Takagi J, Saito Y. Propolypeptide of von Willebrand factor serves as a substrate for Factor XIIIa and is cross-linked to laminin. J Biol Chem 1993; 268: 12311-6.
  • 37 Takagi J, Aoyama T, Ueki S, Ohba H, Saito Y, Lorand L. Identification of factor-XIIIa-reactive glutaminyl residues in the propolypeptide of bovine von Willebrand factor. Eur J Biochem 1995; 232: 773-7.
  • 38 Royo T, Vidal M, Badimon L. Purification of the porcine platelet GP IIb-IIIa complex and the propolypeptide of von Willebrand factor. Thromb Haemost. 1998 in press.
  • 39 Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
  • 40 Tandon NN, Lipsky RH, Burgess WH, Jamieson GA. Isolation and characterization of platelet Glycoprotein IV (CD36). J Biol Chem 1989; 264: 7570-5.
  • 41 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
  • 42 Douvas AS, Stumph WE, Reyes P, Tan EM. Isolation and characterization of nuclear ribonucleoprotein complexes using human anti-nuclear ribonucleoprotein antibodies. J Biol Chem 1979; 254: 3608-16.
  • 43 Usui T, Fujisawa T, Takagi J, Saito Y. Propolypeptide and mature portions of von Willebrand factor of bovine origin recognize different sites on type-I collagen obtained from bovine tendom. Eur J Biochem 1992; 205: 363-7.
  • 44 Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4.
  • 45 Mancuso DJ, Tuley EA, Westfield LA, Worrall NK, Shelton-Inloes BB, Sorace JM, Alevy YG, Sadler JE. Structure of the gene for human von Willebrand factor. J Biol Chem 1989; 264: 19514-27.
  • 46 Wilbourn B, Harrison P, Lawrie A, Savariau E, Savidge G, Cramer EM. Porcine platelets contain an increased quantity of ultra-high molecular weight von Willebrand factor and numerous alpha-granular tubular structures. Br J Haematol 1993; 83: 608-15.
  • 47 Cramer EM, Caen JP, Drouet L, Gorius B. Absence of tubular structures and immunolabelling for von Willebrand factor in the platelet alpha-granules from porcine von Willebrand disease. Blood 1986; 68: 774-8.
  • 48 Roussi J, Drouet L, Sigman J, Vaiman M, Pignaud G, Bonneau M, Masse JM, Cramer EM. Absence of incorporation of plasma von Willebrand factor into porcine platelet alpha-granules. Br J Haematol 1995; 90: 661-8.
  • 49 Fitzgerald LA, Leung B, Phillips DR. A method for purifying the platelet membrane glycoprotein IIb-IIIa complex. Anal Biochem 1985; 151: 169-77.
  • 50 Romeuf C, Mazurier C. Evidence that von Willebrand factor antigen II interacts with mature platelet and plasma von Willebrand factor (abstract). Thromb Haemost. 1997 Suppl. #PS-2630.
  • 51 Borchiellini A, Fijnvandraat K, Cate JW, Pajkrt D, Deventer SJH, Pasterkamp G, Meijer-Huizinga F, Zwart-Huinink L, Voorberg J, Mourik JA. Quantitative analysis of von Willebrand factor propeptide release in vivo: Effect of experimental endotoxemia and administration of 1-deamino-8-Darginine vasopressin in humans. Blood 1996; 88: 2951-8.
  • 52 Vischer UM, Ingerslev J, Wollheim CB, Mestries JC, Tsakiris DA, Haefeli WE, Kruithof EKO. Acute von Willebrand factor secretion from the endothelium in vivo: Assessment through plasma propeptide (vWf:AgII) levels. Thromb Haemost 1997; 77: 387-93.
  • 53 Kornfeld K, Reitman ML, Kornfeld R. The carbohydrate-binding specificity of pea and lentil lectins. Fucose is an important determinant. J Biol Chem 1981; 256: 6633-40.